貨號(hào)：GS40194

Dresbuxelimab (formerly AK119) is a humanized monoclonal antibody developed by Akeso Biopharma that targets CD73 (ecto-5'-nucleotidase). It is being investigated as an immunotherapy for cancer, aiming to inhibit the adenosine-mediated immunosuppressive pathway within the tumor microenvironment. By blocking CD73, dresbuxelimab seeks to enhance anti-tumor immune responses and is evaluated in clinical trials, often in combination with other immunotherapies such as PD-1/PD-L1 inhibitors, for the treatment of advanced solid tumors.